Literature DB >> 12492617

Association between the N-acetylation genetic polymorphism and bronchial asthma.

Muradiye Nacak1, A Sükrü Aynacioglu, Ayten Filiz, Ingolf Cascorbi, M Emin Erdal, Necat Yilmaz, Erhan Ekinci, Ivar Roots.   

Abstract

AIMS: Since polymorphic N-acetyltransferase 2 (NAT2) has been suggested as a susceptibility factor for atopic diseases, the study was undertaken to investigate whether an association exists between acetylation polymorphism and asthma patients with atopy.
METHODS: The frequencies of NAT2 alleles and genotypes were determined by PCR/RFLP in a total of 210 asthma patients (extrinsic (n = 108) and intrinsic (n = 102) asthmatics) and 240 control subjects. Presence of the NAT2*4 (wild-type) allele defined a NAT2 genotype as rapid and combinations of mutant alleles NAT2*5 A, *5B, *5C, *6 A, and *7B as slow.
RESULTS: Genotypes coding for slow acetylation were detected in 70.4, 58.4 and 58.3% of extrinsic asthmatics, but intrinsic asthmatics and control subjects, respectively. The frequency of slow acetylators was higher among extrinsic asthmatics than intrinsic asthmatics, this difference did not reach statistical significance (odds ratio 1.02, 95% confidence interval 0.64, 1.63, P = 0.085). However, we found a relatively moderate, but significantly higher, increased frequency of slow acetylators among extrinsic asthma patients compared with control subjects (odds ratio 1.70, 95% confidence interval 1.04, 2.76, P = 0.042).
CONCLUSIONS: This study shows an association between acetylation polymorphism and susceptibility to extrinsic asthma, but not to intrinsic asthma, suggesting a minor role of the NAT2 polymorphism in the development of atopic asthma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12492617      PMCID: PMC1874484          DOI: 10.1046/j.1365-2125.2002.01670.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Efficiency of some in vitro allergy tests for evaluating atopy in children and adults.

Authors:  N Yilmaz; Z Bayraktaroğlu; J Ozaslan
Journal:  Clin Chem Lab Med       Date:  1999-10       Impact factor: 3.694

Review 2.  N-acetylation pharmacogenetics.

Authors:  W W Weber; D W Hein
Journal:  Pharmacol Rev       Date:  1985-03       Impact factor: 25.468

Review 3.  The immunology of extrinsic and intrinsic asthma.

Authors:  C Walker
Journal:  Agents Actions Suppl       Date:  1993

4.  Acetylator phenotypes and type I (insulin-dependent) diabetics with microvascular disease.

Authors:  H J Bodansky; P L Drury; A G Cudworth; D A Evans
Journal:  Diabetes       Date:  1981-11       Impact factor: 9.461

5.  Acetylator phenotype in patients with allergic diseases and its clinical significance.

Authors:  K Orzechowska-Juzwenko; P Milejski; J Patkowski; M Nittner-Marszalska; J Malolepszy
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1990-10

6.  Relationship between acetylation polymorphism and risk of atopic diseases.

Authors:  B Gawrońska-Szklarz; T Luszawska-Kutrzeba; G Czaja-Bulsa; G Kurzawski
Journal:  Clin Pharmacol Ther       Date:  1999-05       Impact factor: 6.875

7.  N-Acetyltransferase genotypes as modifiers of diisocyanate exposure-associated asthma risk.

Authors:  Harriet Wikman; Päivi Piirilä; Christina Rosenberg; Ritva Luukkonen; Katja Kääriä; Henrik Nordman; Hannu Norppa; Harri Vainio; Ari Hirvonen
Journal:  Pharmacogenetics       Date:  2002-04

8.  Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes.

Authors:  D W Hein; R J Ferguson; M A Doll; T D Rustan; K Gray
Journal:  Hum Mol Genet       Date:  1994-05       Impact factor: 6.150

9.  Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children.

Authors:  M R Sears; B Burrows; E M Flannery; G P Herbison; C J Hewitt; M D Holdaway
Journal:  N Engl J Med       Date:  1991-10-10       Impact factor: 91.245

Review 10.  Nomenclature for N-acetyltransferases.

Authors:  K P Vatsis; W W Weber; D A Bell; J M Dupret; D A Evans; D M Grant; D W Hein; H J Lin; U A Meyer; M V Relling
Journal:  Pharmacogenetics       Date:  1995-02
View more
  5 in total

1.  The effect of Shoseiryuto, a traditional Japanese medicine, on cytochrome P450s, N-acetyltransferase 2 and xanthine oxidase, in extensive or intermediate metabolizers of CYP2D6.

Authors:  Masashi Nakao; Yousuke Muramoto; Motoko Hisadome; Naoko Yamano; Mami Shoji; Yumi Fukushima; Junji Saruwatari; Kazuko Nakagawa
Journal:  Eur J Clin Pharmacol       Date:  2007-02-13       Impact factor: 2.953

2.  NAT2 slow acetylation genotypes contribute to asthma risk among Caucasians: evidence from 946 cases and 1,091 controls.

Authors:  Yan Wang; Qiao Zhang; Mingzhou Zhang; Changzheng Wang
Journal:  Mol Biol Rep       Date:  2014-01-19       Impact factor: 2.316

3.  N-Acetyltransferase 2 Genotypes Are Associated With Diisocyanate-Induced Asthma.

Authors:  Berran Yucesoy; Grace E Kissling; Victor J Johnson; Zana L Lummus; Denyse Gautrin; André Cartier; Louis-Philippe Boulet; Joaquin Sastre; Santiago Quirce; Susan M Tarlo; Maria-Jesus Cruz; Xavier Munoz; Michael I Luster; David I Bernstein
Journal:  J Occup Environ Med       Date:  2015-12       Impact factor: 2.162

4.  Protective role of glutathione S-transferase P1 (GSTP1) Val105Val genotype in patients with bronchial asthma.

Authors:  A Sükrü Aynacioglu; Muradiye Nacak; Ayten Filiz; Erhan Ekinci; Ivar Roots
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

Review 5.  Association studies for asthma and atopic diseases: a comprehensive review of the literature.

Authors:  Sabine Hoffjan; Dan Nicolae; Carole Ober
Journal:  Respir Res       Date:  2003-12-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.